 Samantha Kendrick
Concepts (188)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lymphoma, Large B-Cell, Diffuse | 11 | 2024 | 110 | 4.260 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 9 | 2026 | 128 | 3.740 |
Why?
| | Proto-Oncogene Proteins c-myc | 4 | 2026 | 55 | 2.010 |
Why?
| | Cytidine Deaminase | 2 | 2026 | 13 | 1.630 |
Why?
| | Promoter Regions, Genetic | 6 | 2026 | 465 | 1.370 |
Why?
| | DNA | 4 | 2026 | 535 | 1.220 |
Why?
| | Lymphoma | 2 | 2024 | 71 | 0.940 |
Why?
| | G-Quadruplexes | 3 | 2026 | 77 | 0.780 |
Why?
| | CARD Signaling Adaptor Proteins | 1 | 2022 | 6 | 0.750 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2024 | 175 | 0.710 |
Why?
| | Lung Neoplasms | 2 | 2024 | 645 | 0.660 |
Why?
| | HIV Infections | 2 | 2020 | 402 | 0.600 |
Why?
| | Gene Expression Profiling | 5 | 2019 | 1112 | 0.540 |
Why?
| | Histocompatibility Antigens Class II | 1 | 2016 | 35 | 0.510 |
Why?
| | Piperidines | 2 | 2014 | 98 | 0.500 |
Why?
| | Cytoplasm | 1 | 2016 | 93 | 0.490 |
Why?
| | Pregnanediol | 1 | 2014 | 1 | 0.420 |
Why?
| | Gene Amplification | 1 | 2014 | 58 | 0.420 |
Why?
| | Thermodynamics | 1 | 2014 | 34 | 0.420 |
Why?
| | RNA, Messenger | 5 | 2020 | 1133 | 0.410 |
Why?
| | Gene Expression | 1 | 2015 | 618 | 0.390 |
Why?
| | Antineoplastic Agents | 2 | 2019 | 1232 | 0.380 |
Why?
| | Herpesvirus 8, Human | 2 | 2023 | 98 | 0.330 |
Why?
| | Humans | 24 | 2026 | 53230 | 0.330 |
Why?
| | Antibodies, Monoclonal | 1 | 2014 | 477 | 0.320 |
Why?
| | GC Rich Sequence | 1 | 2009 | 1 | 0.320 |
Why?
| | Oncogenes | 2 | 2022 | 61 | 0.260 |
Why?
| | Genes, myc | 2 | 2020 | 39 | 0.260 |
Why?
| | Animals | 9 | 2024 | 13526 | 0.250 |
Why?
| | Protein Binding | 2 | 2026 | 670 | 0.250 |
Why?
| | Deamination | 1 | 2026 | 1 | 0.240 |
Why?
| | Pregnanes | 2 | 2017 | 3 | 0.240 |
Why?
| | Cell Line, Tumor | 4 | 2024 | 1470 | 0.240 |
Why?
| | Benzoxazines | 2 | 2017 | 18 | 0.240 |
Why?
| | Mice | 4 | 2024 | 5982 | 0.230 |
Why?
| | Bone Marrow | 3 | 2022 | 359 | 0.230 |
Why?
| | Epstein-Barr Virus Infections | 2 | 2022 | 32 | 0.220 |
Why?
| | Neoplasm, Residual | 2 | 2022 | 171 | 0.200 |
Why?
| | Prognosis | 3 | 2021 | 2118 | 0.200 |
Why?
| | Lymphoma, Primary Effusion | 1 | 2023 | 19 | 0.190 |
Why?
| | Multiple Myeloma | 3 | 2022 | 3082 | 0.190 |
Why?
| | Guanylate Cyclase | 1 | 2022 | 9 | 0.190 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2022 | 85 | 0.180 |
Why?
| | Furans | 1 | 2022 | 30 | 0.180 |
Why?
| | Sarcoma, Kaposi | 1 | 2023 | 77 | 0.180 |
Why?
| | Small Cell Lung Carcinoma | 1 | 2022 | 30 | 0.180 |
Why?
| | Genetic Pleiotropy | 1 | 2011 | 2 | 0.170 |
Why?
| | Genes, src | 1 | 2011 | 2 | 0.170 |
Why?
| | Rous sarcoma virus | 1 | 2011 | 4 | 0.170 |
Why?
| | Cell Transformation, Viral | 1 | 2011 | 25 | 0.170 |
Why?
| | Transcription Factor AP-1 | 1 | 2011 | 62 | 0.170 |
Why?
| | HIV Seronegativity | 1 | 2020 | 3 | 0.170 |
Why?
| | TNF Receptor-Associated Factor 3 | 1 | 2020 | 13 | 0.170 |
Why?
| | Apoptosis | 2 | 2017 | 1139 | 0.170 |
Why?
| | Lectins, C-Type | 1 | 2020 | 30 | 0.170 |
Why?
| | HIV Seropositivity | 1 | 2020 | 28 | 0.170 |
Why?
| | Cell Adhesion Molecules | 1 | 2020 | 88 | 0.160 |
Why?
| | Lymphoma, B-Cell | 1 | 2020 | 60 | 0.160 |
Why?
| | Tissue Array Analysis | 3 | 2015 | 45 | 0.160 |
Why?
| | Protein Interaction Mapping | 1 | 2020 | 38 | 0.160 |
Why?
| | Receptors, Cell Surface | 1 | 2020 | 109 | 0.160 |
Why?
| | Bone Diseases | 1 | 2021 | 94 | 0.160 |
Why?
| | Oncogenic Viruses | 1 | 2019 | 15 | 0.160 |
Why?
| | Ethanol | 1 | 2022 | 338 | 0.160 |
Why?
| | Tumor Virus Infections | 1 | 2019 | 46 | 0.160 |
Why?
| | Xenograft Model Antitumor Assays | 2 | 2017 | 228 | 0.150 |
Why?
| | B-Lymphocytes | 1 | 2020 | 178 | 0.150 |
Why?
| | Phosphoproteins | 1 | 2020 | 117 | 0.150 |
Why?
| | Cyclophosphamide | 2 | 2017 | 178 | 0.150 |
Why?
| | Fibroblasts | 1 | 2011 | 363 | 0.150 |
Why?
| | Genomic Instability | 1 | 2019 | 88 | 0.150 |
Why?
| | Cell Line | 2 | 2020 | 1016 | 0.140 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 4 | 2019 | 1043 | 0.140 |
Why?
| | Computational Biology | 1 | 2020 | 209 | 0.140 |
Why?
| | Immunohistochemistry | 3 | 2019 | 975 | 0.140 |
Why?
| | Software | 1 | 2020 | 280 | 0.140 |
Why?
| | DNA Repair | 1 | 2019 | 197 | 0.140 |
Why?
| | Ellipticines | 1 | 2017 | 2 | 0.130 |
Why?
| | Proteomics | 1 | 2020 | 336 | 0.130 |
Why?
| | In Situ Hybridization | 2 | 2014 | 69 | 0.130 |
Why?
| | Caspase 3 | 1 | 2017 | 92 | 0.130 |
Why?
| | MCF-7 Cells | 2 | 2014 | 65 | 0.130 |
Why?
| | Gene Knockdown Techniques | 1 | 2017 | 109 | 0.130 |
Why?
| | Mice, SCID | 2 | 2015 | 180 | 0.130 |
Why?
| | Tumor Burden | 1 | 2017 | 132 | 0.130 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2019 | 350 | 0.130 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 1 | 2016 | 46 | 0.130 |
Why?
| | Tumor Cells, Cultured | 2 | 2015 | 441 | 0.130 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2022 | 610 | 0.130 |
Why?
| | Gene Expression Regulation | 1 | 2011 | 1003 | 0.120 |
Why?
| | Structure-Activity Relationship | 2 | 2014 | 396 | 0.120 |
Why?
| | Transcription Factors | 2 | 2023 | 571 | 0.120 |
Why?
| | Disease-Free Survival | 1 | 2016 | 466 | 0.120 |
Why?
| | Drug Delivery Systems | 1 | 2017 | 148 | 0.120 |
Why?
| | Pyridinium Compounds | 1 | 2015 | 20 | 0.110 |
Why?
| | Chorioallantoic Membrane | 1 | 2005 | 1 | 0.110 |
Why?
| | Doxycycline | 1 | 2005 | 33 | 0.110 |
Why?
| | Drug Synergism | 1 | 2015 | 147 | 0.110 |
Why?
| | Epitopes, B-Lymphocyte | 1 | 2014 | 4 | 0.110 |
Why?
| | Neovascularization, Physiologic | 1 | 2005 | 86 | 0.110 |
Why?
| | Cholestanes | 1 | 2014 | 1 | 0.110 |
Why?
| | Heterogeneous-Nuclear Ribonucleoprotein L | 1 | 2014 | 3 | 0.110 |
Why?
| | Sulfonamides | 1 | 2015 | 139 | 0.100 |
Why?
| | Nucleic Acid Conformation | 1 | 2014 | 82 | 0.100 |
Why?
| | Rabbits | 1 | 2014 | 372 | 0.100 |
Why?
| | Multigene Family | 1 | 2013 | 50 | 0.100 |
Why?
| | Molecular Targeted Therapy | 1 | 2013 | 138 | 0.090 |
Why?
| | Base Sequence | 2 | 2010 | 620 | 0.090 |
Why?
| | Retrospective Studies | 2 | 2020 | 6819 | 0.090 |
Why?
| | Herpesvirus 4, Human | 2 | 2022 | 44 | 0.080 |
Why?
| | Signal Transduction | 4 | 2022 | 1748 | 0.080 |
Why?
| | Female | 7 | 2021 | 28782 | 0.080 |
Why?
| | Bromine | 1 | 2009 | 1 | 0.080 |
Why?
| | Deoxyuridine | 1 | 2009 | 1 | 0.080 |
Why?
| | Thymine | 1 | 2009 | 10 | 0.080 |
Why?
| | Base Pairing | 1 | 2009 | 27 | 0.080 |
Why?
| | Aged | 3 | 2021 | 10429 | 0.080 |
Why?
| | Sequence Deletion | 1 | 2009 | 69 | 0.080 |
Why?
| | Circular Dichroism | 1 | 2009 | 42 | 0.080 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2009 | 169 | 0.080 |
Why?
| | Fluorescent Dyes | 1 | 2009 | 90 | 0.080 |
Why?
| | DNA Mutational Analysis | 1 | 2009 | 179 | 0.080 |
Why?
| | Aged, 80 and over | 1 | 2016 | 3494 | 0.070 |
Why?
| | Temperature | 1 | 2009 | 165 | 0.070 |
Why?
| | Anti-Bacterial Agents | 1 | 2005 | 830 | 0.070 |
Why?
| | Chick Embryo | 2 | 2011 | 79 | 0.070 |
Why?
| | Molecular Sequence Data | 1 | 2009 | 759 | 0.070 |
Why?
| | Middle Aged | 3 | 2021 | 13419 | 0.070 |
Why?
| | Young Adult | 1 | 2016 | 4511 | 0.060 |
Why?
| | Male | 4 | 2021 | 27435 | 0.060 |
Why?
| | Adolescent | 1 | 2016 | 6907 | 0.060 |
Why?
| | Adult | 2 | 2019 | 14534 | 0.050 |
Why?
| | Mutation | 1 | 2009 | 1337 | 0.050 |
Why?
| | Histone Deacetylase Inhibitors | 1 | 2023 | 60 | 0.050 |
Why?
| | Tubercidin | 1 | 2022 | 3 | 0.050 |
Why?
| | Amaryllidaceae Alkaloids | 1 | 2022 | 3 | 0.050 |
Why?
| | Phenanthridines | 1 | 2022 | 4 | 0.050 |
Why?
| | Transaminases | 1 | 2022 | 12 | 0.050 |
Why?
| | Adenosine Monophosphate | 1 | 2022 | 14 | 0.050 |
Why?
| | Alanine | 1 | 2022 | 43 | 0.050 |
Why?
| | Cell Cycle Proteins | 1 | 2023 | 170 | 0.040 |
Why?
| | Fos-Related Antigen-2 | 1 | 2011 | 1 | 0.040 |
Why?
| | Virus Activation | 1 | 2022 | 49 | 0.040 |
Why?
| | Cell Line, Transformed | 1 | 2011 | 73 | 0.040 |
Why?
| | Nuclear Proteins | 1 | 2023 | 250 | 0.040 |
Why?
| | SOXC Transcription Factors | 1 | 2021 | 13 | 0.040 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2014 | 1367 | 0.040 |
Why?
| | Proto-Oncogene Proteins c-jun | 1 | 2011 | 76 | 0.040 |
Why?
| | Enzyme Activation | 1 | 2011 | 267 | 0.040 |
Why?
| | Amino Acid Motifs | 1 | 2020 | 59 | 0.040 |
Why?
| | Workflow | 1 | 2020 | 53 | 0.040 |
Why?
| | Transplantation, Autologous | 1 | 2022 | 488 | 0.040 |
Why?
| | Immunotherapy | 1 | 2022 | 266 | 0.040 |
Why?
| | Databases, Genetic | 1 | 2020 | 82 | 0.040 |
Why?
| | Survival Analysis | 1 | 2021 | 659 | 0.040 |
Why?
| | Comparative Genomic Hybridization | 1 | 2019 | 38 | 0.040 |
Why?
| | Mass Spectrometry | 1 | 2020 | 294 | 0.040 |
Why?
| | Gene Regulatory Networks | 1 | 2019 | 112 | 0.040 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2022 | 647 | 0.030 |
Why?
| | Bone and Bones | 1 | 2021 | 501 | 0.030 |
Why?
| | Indolizines | 1 | 2015 | 5 | 0.030 |
Why?
| | Cyclic N-Oxides | 1 | 2015 | 12 | 0.030 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2019 | 868 | 0.030 |
Why?
| | Mice, Inbred NOD | 1 | 2015 | 90 | 0.030 |
Why?
| | Immunoenzyme Techniques | 1 | 2015 | 134 | 0.030 |
Why?
| | Arkansas | 1 | 2021 | 2068 | 0.030 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2015 | 181 | 0.030 |
Why?
| | Chickens | 1 | 2005 | 106 | 0.030 |
Why?
| | Cell Culture Techniques | 1 | 2005 | 99 | 0.030 |
Why?
| | Models, Animal | 1 | 2005 | 233 | 0.030 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2015 | 579 | 0.030 |
Why?
| | Molecular Diagnostic Techniques | 1 | 2013 | 30 | 0.020 |
Why?
| | Colorimetry | 1 | 2013 | 16 | 0.020 |
Why?
| | Vincristine | 1 | 2013 | 89 | 0.020 |
Why?
| | Gene Dosage | 1 | 2013 | 76 | 0.020 |
Why?
| | Prednisone | 1 | 2013 | 101 | 0.020 |
Why?
| | Recombinant Proteins | 1 | 2014 | 489 | 0.020 |
Why?
| | DNA, Neoplasm | 1 | 2013 | 146 | 0.020 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2013 | 266 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2022 | 5595 | 0.020 |
Why?
| | Translocation, Genetic | 1 | 2013 | 266 | 0.020 |
Why?
| | Doxorubicin | 1 | 2013 | 247 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2015 | 1031 | 0.020 |
Why?
| | Lymph Nodes | 1 | 2013 | 252 | 0.020 |
Why?
| | Models, Biological | 1 | 2013 | 737 | 0.020 |
Why?
| | Survival Rate | 1 | 2013 | 949 | 0.020 |
Why?
| | Transcriptional Activation | 1 | 2010 | 128 | 0.020 |
Why?
| | Neoplasms | 1 | 2010 | 1334 | 0.010 |
Why?
|
|
Kendrick's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|